The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Improvement of hepatorenal syndrome with extracorporeal albumin dialysis mars: Results of a prospective, randomized, controlled clinical trial
Open accessAbstract
In hepatorenal syndrome (HRS), renal insufficiency is often progressive, and the prognosis is extremely poor under standard medical therapy. The molecular adsorbent recirculating system (MARS) is a modified dialysis method using an albumin-containing dialysate that is recirculated and perfused online through charcoal and anion-exchanger columns. MARS enables the selective removal of albumin-bound substances. A prospective controlled trial was performed to determine the effect of MARS treatment on 30-day survival in patients with type I HRS at high risk (bilirubin level, ≥15 mg/dL) compared with standard treatment. Thirteen patients with cirrhosis with type I HRS were included from 1997 to 1999. All were Child’s class C, with Child-Turcotte-Pugh scores of 12.4 ± 1.0, United Network for Organ Sharing status 2A, and total bilirubin values of 25.7 ± 14.0 mg/dL. Eight patients were treated with the MARS method in addition to hemodiafiltration (HDF) and standard medical therapy, and 5 patients were in the control group (HDF and standard medical treatment alone). None of these patients underwent liver transplantation or received a transjugular intrahepatic portosystemic shunt or vasopressin analogues during the observation period. In the MARS group, 5.2 ± 3.6 treatments (range, 1 to 10 treatments) were performed for 6 to 8 hours daily per patient. A significant decrease in bilirubin and creatinine levels (P< .01) and increase in serum sodium level and prothrombin activity (P< .01) were observed in the MARS group. Mortality rates were 100% in the control group at day 7 and 62.5% in the MARS group at day 7 and 75% at day 30, respectively (P< .01). We conclude that the removal of albumin-bound substances with the MARS method can contribute to the treatment of type I HRS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941
Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis†
Arroyo, V, Ginès, P., Gerbes, A. L., Dudley, F. J., Gentilini, P., Laffi, G., Reynolds, T. B., Ring-Larsen, H., & Schölmerich, J. (1996) · Hepatology · doi:10.1002/hep.510230122 · Cited by 1,703
Corticosteroid therapy of alcoholic hepatitis
Maddrey, W. C., Boitnott, J. K., Bedine, M. S., Weber, F. L., Mezey, E., & White, R. I. (1978) · Gastroenterology · doi:10.1016/0016-5085(78)90401-8 · Cited by 925
Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites
Ginès, A., Escorsell, A., Ginès, P., Saló, J., Jiménez, W., Inglada, L., Navasa, M., Clària, J., Rimola, A., Arroyo, V., et al. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90031-7 · Cited by 891
Stange, Mitzner, Risler, Erley, Lauchart, Goehl, Klammt, S., Peszynski, Freytag, Hickstein, et al. (1999) · Artificial Organs · doi:10.1046/j.1525-1594.1999.06122.x · Cited by 604
Self-citationReversal of Type 1 Hepatorenal Syndrome With the Administration of Midodrine and Octreotide
Angeli, P., Volpin, R., Gerunda, G., Craighero, R., Roner, P., Merenda, R., Amodio, P., Sticca, A., Caregaro, L., Maffei-Faccioli, A., et al. (1999) · Hepatology · doi:10.1002/hep.510290629 · Cited by 564
Watanabe, F. D., Mullon, C. J.-P., Hewitt, W. R., Arkadopoulos, N., Kahaku, E., Eguchi, S., Khalili, T., Arnaout, W., Shackleton, C. R., Rozga, J., et al. (1997) · Annals of Surgery · doi:10.1097/00000658-199705000-00005 · Cited by 453
Guevara, M., Ginès, P., Bandi, J. C., Gilabert, R., Sort, P., Jiménez, W., Garcia-Pagán, J. C., Bosch, J., Arroyo, V., & Rodés, J. (1998) · Hepatology · doi:10.1002/hep.510280219 · Cited by 425
Planas, R., Bataller, R., & Rodés, J. (2000) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-000-0032-9 · Cited by 332
Epstein, M. (1996) · Hanley & Belfus eBooks · Cited by 297
The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): state of the art
Rössle, M., Siegerstetter, V., Huber, M., & Ochs, A. (1998) · Liver · doi:10.1111/j.1600-0676.1998.tb00132.x · Cited by 241
Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients.
Salerno, F., Borroni, G., Moser, P., Badalamenti, S., Cassarà, L., Maggi, A. C., Fusini, M., & Cesana, B. M. (1993) · PubMed · Cited by 203
Stange, J., & Mitzner, S. R. (1996) · The International Journal of Artificial Organs · doi:10.1177/039139889601901109 · Cited by 136
Self-citationAngeli, P., Volpin, R., Piovan, D., Bortoluzzi, A., Craighero, R., Bottaro, S., Finucci, G. F., Casiglia, E., Sticca, A., Toni, R. D., et al. (1998) · Hepatology · doi:10.1002/hep.510280407 · Cited by 136
Keller, F., Heinze, H., Jochimsen, F., Paszfall, J., Schuppan, D., & Buttner, P. G. (1995) · Renal Failure · doi:10.3109/08860229509026250 · Cited by 87
Long term treatment of patients with acute exacerbation of chronic liver failure by albumin dialysis
Seige, M., Kreymann, B., Jeschke, B., et al. (1999) · Transplantation Proceedings · doi:10.1016/s0041-1345(98)02033-8 · Cited by 68
Review article: liver support systems in acute hepatic failure
Rahman, & Hodgson (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00597.x · Cited by 52
Eisenman, A., Armali, Z., Enat, R., Bankir, L., & Baruch, Y. (1999) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1999.00556.x · Cited by 32
Transjugular Intrahepatic Portosystemic Stent Shunt for Hepatorenal Syndrome and Ascites
Wong, F. (1998) · Digestion · doi:10.1159/000051419 · Cited by 10
Hepatorenal syndrome and ascites — an introduction
Geñtilini, P. (1999) · Liver International · doi:10.1111/j.1478-3231.1999.tb00091.x · Cited by 7
Research works printed but not linked: 18
- Arroyo, 1992, Arteriolar vasodilation and the pathogenesis of the hyperdynamic circulation and renal sodium and water retention in cirrhosis, Gastroenterology, 102, 1077, 10.1016/0016-5085(92)90203-B · doi:10.1016/0016-5085(92)90203-b
- Earley, 1979, Hepatorenal syndrome, 495
- Epstein, 1997, Hepatorenal syndrome: Emerging perspectives, Semin Nephrol, 17, 563
- Gentilini, 1999, Hepatorenal syndrome and its treatment today, Eur J Gastroenterol Hepatol, 11, 1061, 10.1097/00042737-199909000-00021 · doi:10.1097/00042737-199909000-00021
- Eckardt, 1999, Renal failure in liver disease, Intensive Care Med, 25, 5, 10.1007/s001340050780 · doi:10.1007/s001340050780
- Brensing, 1999, Treatment of liver disease, 53
- Gulberg, 1998, Successful conservative therapy of hepatorenal syndrome with vasopressin I receptor antagonist ornipressin, Z Gastroenterol, 36, 1053
- Ganne-Carrie, 1996, Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation, Dig Dis Sci, 41, 1054
- Gulberg, 1999, Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine, Hepatology, 30, 870, 10.1002/hep.510300430 · doi:10.1002/hep.510300430
- Hadengue, 1998, Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome, J Hepatol, 29, 565, 10.1016/S0168-8278(98)80151-7 · doi:10.1016/s0168-8278(98)80151-7
- Kaplan, 1997, Extracorporeal blood purification in the management of patients with hepatic failure, Semin Nephrol, 17, 576
- Hughes, 1997, Acute liver failure, 278
- Awad, 1997, Characteristics of an albumin dialysate hemodiafiltration system for the clearance of unconjugated bilirubin, ASAIO J, 43, M745, 10.1097/00002480-199703000-00056 · doi:10.1097/00002480-199703000-00056
- Kreymann, 1999, Albumin dialysis: Effective removal of copper in a patient with fulminant Wilson disease and successful bridging to liver transplantation: A new possibility for the elimination of protein-bound toxins, J Hepatol, 31, 1080, 10.1016/S0168-8278(99)80322-5 · doi:10.1016/s0168-8278(99)80322-5
- Mitzner, 1999, Albumin dialysis “MARS.” Clinical results in extracorporeal treatment of hepatorenal syndrome [abstract], Hepatology, 30, S418A
- Awad, 1999, Can the clearance of tumor necrosis factor-alpha and interleukin 6 be enhanced using an albumin dialysate hemodiafiltration system?, ASAIO J, 45, 47, 10.1097/00002480-199901000-00011 · doi:10.1097/00002480-199901000-00011
- Loock, 1997, Change of human serum amino acid patterns (Fischer index) during a new dialysis treatment for liver failure (MARS) [abstract], Int J Artif Organs, 20, 500A
- Perez, 1996, The kidney in liver diseaseed 4, 517
Cited by
(2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.004 · Cited by 1,725
Sarin, S. K., Kedarisetty, C. K., Abbas, Z., Amarapurkar, D., Bihari, C., Chan, A. C. Y., Chawla, Y. K., Dokmeci, A. K., Garg, H., Ghazinyan, H., et al. (2014) · Hepatology International · doi:10.1007/s12072-014-9580-2 · Cited by 1,481
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis
Salerno, F., Gerbes, A., Ginès, P., Wong, F., & Arroyo, V. (2008) · Postgraduate Medical Journal · doi:10.1136/gut.2006.107789 · Cited by 1,081
Practical Aspects of the Ligand-Binding and Enzymatic Properties of Human Serum Albumin.
Kragh-Hansen, U., Chuang, V. T. G., & Otagiri, M. (2002) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.25.695 · Cited by 892
APASL ACLF Research Consortium (AARC) for APASL ACLF working Party., Sarin, S. K., Choudhury, A., Sharma, M. K., Maiwall, R., Al Mahtab, M., Rahman, S., Saigal, S., Saraf, N., Soin, A. S., et al. (2019) · Hepatology International · doi:10.1007/s12072-019-09946-3 · Cited by 884
Metadata
- Authors
- Mitzner, S. R., Stange, J., Klammt, S., Risler, T., Erley, C. M., Bader, B. D., Berger, E. D., Lauchart, W., Peszynski, P., Freytag, J., Hickstein, H., Loock, J., Löhr, J.-M., Liebe, S., Emmrich, J., Korten, G., & Schmidt, R.
- Venue
- Liver Transplantation
- Published
- 2000-05
- Volume
- 6
- Issue
- 3
- Pages
- 277-286
- ISSN
- 1527-6465 (ISSN-L)
- OpenAlex
- W2073024831
- Cited by
- 717
- References
- 20
- FWCI
- 28.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 5601 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.